Profound Medical Corporation (PROF) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’

TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 144 - Report of proposed sale of securities

Profound Medical to Participate in the Stifel 2024 Healthcare Conference

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical Announces Third Quarter 2024 Financial Results

TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired...

Form 144 - Report of proposed sale of securities